Patrick J Blatchford

A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01)

A. Barzi, W. Messersmith, H. Hochster, 2020, Cancer research communications.

Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms

A. Thorburn, Jihye Kim, S. Eckhardt, 2018, Molecular Cancer Therapeutics.

Potent antitumor activity of cabozantinib, a c‐MET and VEGFR2 inhibitor, in a colorectal cancer patient‐derived tumor explant model

C. Atreya, A. Tan, R. Kelley, 2015, International journal of cancer.

Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes

Matthew S. Lewis, S. Eckhardt, T. Pitts, 2021, Frontiers in Immunology.

Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids‐DOTT trial): pilot/feasibility phase findings

J. Halperin, N. Stence, P. Steg, 2015, Journal of thrombosis and haemostasis : JTH.

High incidence of prolonged rectal bleeding and advanced stage cancer in early-onset colorectal cancer patients

Swati G. Patel, M. Brown, M. McCarter, 2020 .

A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer

A. Jimeno, D. Gao, S. Kopetz, 2016, International journal of cancer.

A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer

T. Pitts, S. Bagby, Tyler Friedrich, 2024, Clinical cancer research : an official journal of the American Association for Cancer Research.

Oral Iloprost Improves Endobronchial Dysplasia in Former Smokers

Y. Miller, J. Minna, P. Massion, 2011, Cancer Prevention Research.

Bronchial Epithelial Ki-67 Index Is Related to Histology, Smoking, and Gender, but Not Lung Cancer or Chronic Obstructive Pulmonary Disease

T. Byers, Y. Miller, F. Hirsch, 2007, Cancer Epidemiology Biomarkers & Prevention.

The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy

T. Pitts, J. Arcaroli, W. Messersmith, 2017, Oncotarget.